Sofgen Pharma S.A.

Total Valuation

Sofgen Pharma S.A. carries a market capitalization of 232,724.00, placing it among publicly traded companies globally. Its enterprise value stands at 686.25M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Sofgen Pharma S.A. currently has 101.11M shares outstanding.

Valuation Ratios

Sofgen Pharma S.A. trades at a trailing price-to-earnings ratio of 10.20. The price-to-sales ratio is 0.97, and the price-to-book ratio stands at 1,959.60.

Enterprise Valuation

On an enterprise value basis, Sofgen Pharma S.A. trades at an EV/EBITDA multiple of 10.99 and an EV/FCF ratio of 3.89. The EV/Sales ratio of 1.62 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 15.50 provides insight into valuation relative to core operating earnings.

Financial Position

Sofgen Pharma S.A. maintains a current ratio of 0.64, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -40,693.34, indicating conservative leverage, while an interest coverage ratio of 1.53 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Sofgen Pharma S.A. has paid 5.62M in income taxes, reflecting an effective tax rate of 12.22.

Stock Price Statistics

Sofgen Pharma S.A.'s stock has declined approximately -99.99225% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.03.

Income Statement

Over the trailing twelve months, Sofgen Pharma S.A. generated 423.75M in revenue and converted that into 40.34M in net income, yielding earnings per share of 0.40. EBITDA reached 62.47M, while operating income came in at 44.28M.

Balance Sheet

Sofgen Pharma S.A. holds 23.82M in cash and equivalents against 299.50M in total debt, resulting in a net debt position of 281.99M. Total book value stands at 210,000.00, with working capital of -157.92M providing operational flexibility.

Cash Flow

Sofgen Pharma S.A. produced 107.64M in operating cash flow over the past twelve months. After subtracting -32.79M in capital expenditures, free cash flow totaled 74.84M - equivalent to 0.74 per share.

Margins

Sofgen Pharma S.A. operates with a gross margin of 56.16, reflecting its pricing power and cost economics. The operating margin of 10.45 and net profit margin of 9.52 provide insight into operational efficiency.

Dividends & Yields

Scores

Sofgen Pharma S.A. posts an Altman Z-Score of 0.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.